TRCT
LPCN icon

Tower Research Capital (TRC)’s Lipocine LPCN Stock Holding History

Tower Research Capital (TRC)’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.46K Buy
+933
New +$8.13K ﹤0.01% 4008
2025
Q4 		– Sell
-1,170
Closed -$3.33K – 5411
2025
Q3 		$3.33K Buy
1,170
+497
+74% +$1.51K ﹤0.01% 4520
2025
Q2 		$2.13K Sell
673
-564
-46% -$1.83K ﹤0.01% 4694
2025
Q1 		$3.93K Sell
1,237
-229
-16% -$887 ﹤0.01% 4325
2024
Q4 		$7.15K Buy
1,466
+400
+38% +$2.03K ﹤0.01% 4096
2024
Q3 		$4.79K Buy
1,066
+294
+38% +$1.48K ﹤0.01% 4424
2024
Q2 		$6.36K Sell
772
-1,242
-62% -$7.77K ﹤0.01% 4587
2024
Q1 		$10.5K Sell
2,014
-224
-10% -$871 ﹤0.01% 3693
2023
Q4 		$6.24K Buy
2,238
+1,984
+781% +$5.25K ﹤0.01% 4766
2023
Q3 		$757 Sell
254
-1,577
-86% -$6.63K ﹤0.01% 5481
2023
Q2 		$9.23K Buy
1,831
+256
+16% +$1.21K ﹤0.01% 4315
2023
Q1 		$9K Buy
1,575
+425
+37% +$3.28K ﹤0.01% 4507
2022
Q4 		$8K Buy
1,150
+568
+98% +$4.14K ﹤0.01% 4418
2022
Q3 		$4K Buy
+582
New +$6.5K ﹤0.01% 5269
2022
Q2 		– Sell
-503
Closed -$12K – 6334
2022
Q1 		$12K Buy
503
+352
+233% +$7.37K ﹤0.01% 4070
2021
Q4 		$3K Sell
151
-294
-66% -$5.46K ﹤0.01% 5465
2021
Q3 		$8K Buy
+445
New +$9.82K ﹤0.01% 4547
2020
Q3 		– Sell
-1,214
Closed -$26K – 4973
2020
Q2 		$26K Buy
+1,214
New +$15.7K ﹤0.01% 3539
2019
Q4 		– Sell
-3
Closed – – 4014
2019
Q3 		$0 Sell
3
-113
-97% -$4.54K ﹤0.01% 4332
2019
Q2 		$4K Buy
+116
New +$3.58K ﹤0.01% 3032
2018
Q1 		– Sell
-63
Closed -$4K – 3588
2017
Q4 		$4K Sell
63
-55
-47% -$3.42K ﹤0.01% 2995
2017
Q3 		$8K Sell
118
-76
-39% -$5.5K ﹤0.01% 3158
2017
Q2 		$13K Buy
+194
New +$12.7K ﹤0.01% 1456
2017
Q1 		– Sell
-290
Closed -$18.8K – 3541
2016
Q4 		$18K Buy
+290
New +$18.4K ﹤0.01% 2240
2016
Q3 		– Sell
-3
Closed – – 4078
2016
Q2 		$0 Sell
3
-113
-97% -$17.5K ﹤0.01% 4730
2016
Q1 		$20K Buy
+116
New +$19.8K ﹤0.01% 1350
2015
Q4 		– Sell
-29
Closed -$6K – 4798
2015
Q3 		$6K Buy
+29
New +$6.71K ﹤0.01% 2666
2014
Q3 		– Sell
-51
Closed -$5K – 4686
2014
Q2 		$5K Buy
+51
New +$6.1K ﹤0.01% 2858

Other funds holding LPCN

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Tower Research Capital (TRC)'s LPCN Position: Q1 2026 in Review

Tower Research Capital (TRC) opened a new position in Lipocine (LPCN) in Q1 2026: 933 shares worth $7.46K. The stake represents ﹤0.01% of the portfolio and ranks #4008 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in LPCN as recently as Q3 2025.

Tower Research Capital (TRC) first reported a position in LPCN in Q2 2014 and has held it in 28 quarters since. The position peaked at $26K in Q2 2020. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

  • Tower Research Capital (TRC) held 933 shares of Lipocine worth $7.46K as of Q1 2026.
  • Lipocine was a new Tower Research Capital (TRC) position in Q1 2026.
  • Lipocine made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4008 holding.
  • Tower Research Capital (TRC) first reported a position in Lipocine in Q2 2014 and has held it in 28 quarters since.
  • Tower Research Capital (TRC)'s Lipocine position peaked at $26K in Q2 2020.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.